Alpha 2.0
Login Register
» Authors » Janusz Kloczko

Janusz Kloczko

Explore the profile of Janusz Kloczko including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 75
Citations 1333
Followers 0
Related Specialties
Hematology
Oncology
General Medicine
Top 10 Co-Authors
Lukasz Bolkun
Jaroslaw Piszcz
Tadeusz Robak
Krzysztof Warzocha
Sebastian Grosicki
Marzenna Galar
Kazimierz Kuliczkowski
Anna Dmoszynska
Andrzej Hellmann
Dorota Lemancewicz
Published In
Leuk Lymphoma
Pol Arch Med Wewn
Br J Haematol
Thromb Res
Adv Med Sci
Affiliations
Soon will be listed here.
Recent Articles
11.
Very Small Embryonic-Like Stem Cells, Endothelial Progenitor Cells, and Different Monocyte Subsets Are Effectively Mobilized in Acute Lymphoblastic Leukemia Patients after G-CSF Treatment
Eljaszewicz A, Bolkun L, Grubczak K, Rusak M, Wasiluk T, Dabrowska M, et al.
Stem Cells Int . 2018 Jul; 2018:1943980. PMID: 30034479
Background: Acute lymphoblastic leukemia (ALL) is a malignant disease of lymphoid progenitor cells. ALL chemotherapy is associated with numerous side effects including neutropenia that is routinely prevented by the administration...
12.
High chymotrypsin-like activity in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of a better response and longer PFS
Romaniuk W, Bolkun L, Kalita J, Galar M, Bernatowicz M, Ostrowska H, et al.
Ann Hematol . 2018 Jun; 97(10):1879-1887. PMID: 29946907
Proteasome inhibitors (PIs) such as bortezomib constitute an important part of the modern standard therapy for multiple myeloma (MM). In this study, we set out to assess whether proteasome concentration...
13.
Proteasome 20S in multiple myeloma: comparison of concentration and chymotrypsin-like activity in plasma and serum
Romaniuk W, Kalita J, Ostrowska H, Kloczko J
Scand J Clin Lab Invest . 2018 Mar; 78(4):253-257. PMID: 29504425
The ubiquitin-proteasome system is relevant in the pathobiology of many haematological malignancies, including multiple myeloma. The assessment of proteasome concentration and chymotrypsin-like (ChT-L) activity might constitute a new approach to...
14.
Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial
Robak T, Blonski J, Skotnicki A, Piotrowska M, Wrobel T, Rybka J, et al.
Eur J Haematol . 2018 Feb; 100(5):465-474. PMID: 29427355
Objectives: PALG CLL4 is the first, randomized, phase IIIb study with rituximab, cladribine, and cyclophosphamide (RCC) induction and subsequent maintenance with rituximab in previously untreated chronic lymphocytic leukemia (CLL) patients....
15.
Clonal chromosomal aberrations in Philadelphia negative cells such as monosomy 7 and trisomy 8 may persist for years with no impact on the long term outcome in patients with chronic myeloid leukemia
Wasilewska E, Panasiuk B, Gniot M, Sawicka A, Kozlowska K, Lewandowski K, et al.
Cancer Genet . 2017 Oct; 216-217:1-9. PMID: 29025581
The appearance of clonal chromosomal aberrations in Philadelphia negative cells (CCA/Ph-) during the treatment of chronic myeloid leukemia (CML) was recently confirmed. Importance of these findings has not been clearly...
16.
Emergence of a multidrug-resistant Citrobacter freundii ST8 harboring an unusual VIM-4 gene cassette in Poland
Majewski P, Wieczorek P, Lapuc I, Ojdana D, Sienko A, Sacha P, et al.
Int J Infect Dis . 2017 Jun; 61:70-73. PMID: 28602727
Objectives: The growing incidence of multidrug-resistant (MDR) bacteria is an emerging challenge in modern medicine. The utility of carbapenems, which are considered 'last-line' agents, is being diminished by the growing...
17.
Addition of cladribine to the standard induction treatment improves outcomes in a subset of elderly acute myeloid leukemia patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial
Pluta A, Robak T, Wrzesien-Kus A, Budziszewska B, Sulek K, Wawrzyniak E, et al.
Am J Hematol . 2017 Jan; 92(4):359-366. PMID: 28103640
Intensive induction chemotherapy using anthracycline and cytarabine backbone is considered the most effective upfront therapy in physically fit older patients with acute myeloid leukemia (AML). However, outcomes of the standard...
18.
Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia
Robak T, Hellmann A, Kloczko J, Loscertales J, Lech-Maranda E, Pagel J, et al.
Br J Haematol . 2016 Dec; 176(4):618-628. PMID: 27977057
Otlertuzumab (TRU-016) is a humanized anti-CD37 protein therapeutic that triggers direct caspase-independent apoptosis of malignant B cells and induces antibody-dependent cell-mediated cytotoxicity. Patients with relapsed chronic lymphocytic leukaemia (CLL) received...
19.
Involvement of BAFF and APRIL in Resistance to Apoptosis of Acute Myeloid Leukemia
Bolkun L, Grubczak K, Schneider G, Zembko P, Radzikowska U, Singh P, et al.
J Cancer . 2016 Nov; 7(14):1979-1983. PMID: 27877213
B-cell activation factor of the TNF family (BAFF), and a proliferation-inducing ligand (APRIL), two members of the tumour necrosis factor (TNF) superfamily, beyond playing a significant role in normal B-cell...
20.
Health-related quality of life and patient-reported outcomes of ofatumumab plus fludarabine and cyclophosphamide versus fludarabine and cyclophosphamide in the COMPLEMENT 2 trial of patients with relapsed CLL
Robak T, Warzocha K, Govind Babu K, Kulyaba Y, Kuliczkowski K, Abdulkadyrov K, et al.
Leuk Lymphoma . 2016 Nov; 58(7):1598-1606. PMID: 27830957
Chronic lymphocytic leukemia (CLL) is an incurable disease. Quality of life during treatment and periods of subsequent remission is therefore vital. Health-related quality of life (HRQoL) was compared in relapsed...